撒哈拉以南非洲地区使用直接作用抗病毒药物治疗 1 至 5 型丙型肝炎。
Treatment of Hepatitis C Genotypes 1 to 5 in Sub-Saharan Africa Using Direct-Acting Antivirals.
机构信息
College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Adera Gastroenterology and Hepatology Center, Addis Ababa, Ethiopia.
出版信息
Am J Trop Med Hyg. 2020 Nov;103(5):2083-2084. doi: 10.4269/ajtmh.20-0367.
There is limited knowledge of the use of direct acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) in sub-Saharan Africa. We prospectively evaluated individuals infected with HCV genotypes 1 to 5 in Addis Ababa, Ethiopia. Liver fibrosis was assessed by AST-platelet ratio index score and cirrhosis by imaging and laboratory values. All 164 individuals completed treatment. The majority of patients had genotype 4 (76%), and 19% of participants showed evidence of cirrhosis. Sustained virologic response (SVR) across all genotypes was 98.8%. In those with cirrhosis, SVR was 93.5% and in non-cirrhotics 100%. Our study demonstrates broad genotype successful treatment of HCV with DAAs in sub-Saharan Africa, demonstrating the feasibility of HCV elimination in resource-limited settings.
在撒哈拉以南非洲，直接作用抗病毒药物（DAA）治疗丙型肝炎病毒（HCV）的应用知识有限。我们前瞻性地评估了埃塞俄比亚亚的斯亚贝巴感染 HCV 基因型 1 至 5 的个体。肝纤维化通过 AST-血小板比值指数评分评估，肝硬化通过影像学和实验室值评估。所有 164 名患者均完成了治疗。大多数患者为基因型 4（76%），19%的参与者有肝硬化证据。所有基因型的持续病毒学应答（SVR）均为 98.8%。在肝硬化患者中，SVR 为 93.5%，非肝硬化患者为 100%。我们的研究表明，在撒哈拉以南非洲，DAA 对 HCV 的广泛基因型治疗取得了成功，这证明了在资源有限的情况下消除 HCV 的可行性。
Zotero 插件